Evaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant Candidates

Inclusion Criteria: * Patients on the kidney transplant list, waiting for a first or repeat transplant * Presence of anti HLA antibodies either class I and/or II * Sensitized against a potential living donor or have been on the waiting list for at least 3 years and having no potential live-donor * Patients eligible for desensitization will receive either rituximab alone, or rituximab plus apheresis, or tocilizumab before rituximab * Normal recent (\<6 months) cardiac workup * Vaccinated against pneumococcus and meningococcus B and C * Willingness of the patient to undergo the desensitization process and Express consent of the patient * for women of childbearing age, effective contraception or abstinence * Affiliated to a social security scheme or of such a scheme Exclusion Criteria: * Active underlying infections or neoplasia * Pregnant women, parturient or breastfeeding * Subject in exclusion period of another study * Subject under administrative or judicial control * Subject who cannot be contacted in an emergency * Rituximab contra indication: hypersensitivity (to active substance or murine protein), active and severe infections, patients in a severely immunocompromised state, severe heart failure or severe, uncontrolled cardiac disease. * Tocilizumab contra indication: hypersensitivity, active and severe infections. Apheresis contra indication: active and severe infection, untreated or instable coagulation disorders, unstable coronary disease, recent stroke, hemodynamic instability.